Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Cutaneous Melanoma, Stage III Clinical Trial

Official title: Evaluation of the Nutritional Supplement Oncoxin-Viusid® in the Treatment of 20 Patients With Cutaneous Melanoma in Stage IIB-IIIA

Status Completed

Clinical Trial Summary

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.

Clinical Trial Description

Performed at Manuel Fajardo Surgical Clinical University Hospital in Havana, Cuba from September 2014 to April 2018, following a proof of concept open label study, with no control group in 20 patients diagnosed histologically in Fajardo Hospital or Oncology Institute, as Melanoma, primary cutaneous stage IIB-IIIA. All received conventional surgical treatment and oral Oncoxin-Viusid (25 ml 2 times a day for one year), where it was also indicated adjuvant treatment or chemotherapy. All were evaluated monthly the first year and semesterly the second year. Complying with the provisions of the Helsinki Act. ;

Related Conditions & MeSH terms

• Cutaneous Melanoma, Stage II
• Cutaneous Melanoma, Stage III
• Malignant Cutaneous Melanoma
• Melanoma

• NCT number: NCT03541148
• Study type: Interventional
• Source: Catalysis SL
• Status: Completed
• Phase: Phase 2
• Start date: September 16, 2014
• Completion date: April 13, 2018